PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

Jan 11 2010

PhotoMedex (Nasdaq: PHMD) and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (“AK”). Under the terms of the agreement, PhotoMedex’ sales force will promote Galderma’s drug Metvixia® (methyl aminolevulinate) Cream, 16.8% (“Metvixia”) and Galderma’s Aktilite® CL128 LED (light-emitting diode) lamp to healthcare professionals, including dermatologists, plastic surgeons and cosmetic surgeons throughout the United States. Galderma will provide marketing support and distribution. The three-year agreement begins in January; no financial terms have been disclosed.

Actinic keratoses are very common lesions that occur on sun-damaged skin and are widely considered to be a precursor to squamous cell carcinoma.

Metvixia is a topical porphyrin precursor used in photodynamic therapy. When applied to actinic keratosis lesions, Metvixia is selectively absorbed into precancerous cells causing a build-up of endogenous porphyrins. These endogenous porphyrins are illuminated with the Aktilite CL128 lamp emitting a narrow output spectrum of red light with a peak wavelength at 630 nm. Subsequently, a reaction occurs that results in the destruction of the precancerous cells. Clinical trials in various countries with the Metvixia PDT system have shown comparable or better response rates than conventional treatments, such as cryotherapy or surgery. Metvixia PDT selectively targets precancerous cells so the surrounding healthy cells are less subjected to the treatment, therein minimizing scarring and ensuring more acceptable cosmetic outcomes for patients. In clinical trials, the most commonly reported adverse events associated with use of Metvixia PDT were contact sensitization, erythema, pain, burning, and skin discomfort/irritation.